Tibet Rhodiola Pharmaceutical Holding Co

SSE:600211

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Tibet Rhodiola Pharmaceutical Holding Co's stock price target?

Price Target

59.2 CNY

According to Wall Street analysts, the average 1-year price target for Tibet Rhodiola Pharmaceutical Holding Co is 59.2 CNY .

What is Tibet Rhodiola Pharmaceutical Holding Co's Revenue forecast?

Projected CAGR

32%

For the last 8 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's revenue is 11%. The projected CAGR for the next 2 years is 32%.

What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Income forecast?

Projected CAGR

-24%

For the last 8 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's operating income is 43%. The projected CAGR for the next 6 years is -24%.

What is Tibet Rhodiola Pharmaceutical Holding Co's Net Income forecast?

Projected CAGR

29%

For the last 8 years the compound annual growth rate for Tibet Rhodiola Pharmaceutical Holding Co's net income is 31%. The projected CAGR for the next 3 years is 29%.